Pages that link to "Q34802959"
Jump to navigation
Jump to search
The following pages link to Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies (Q34802959):
Displaying 50 items.
- Interventions for reducing inflammation in familial Mediterranean fever (Q24187197) (← links)
- The inflammasomes (Q24304087) (← links)
- Staphylococcus aureus α-hemolysin mediates virulence in a murine model of severe pneumonia through activation of the NLRP3 inflammasome (Q24863277) (← links)
- Interleukin-1 in the pathogenesis and treatment of inflammatory diseases (Q24606766) (← links)
- Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*) (Q24631660) (← links)
- Targeting the Innate Immune Response to Improve Cardiac Graft Recovery after Heart Transplantation: Implications for the Donation after Cardiac Death (Q26744359) (← links)
- From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection (Q26770209) (← links)
- To Extinguish the Fire from Outside the Cell or to Shutdown the Gas Valve Inside? Novel Trends in Anti-Inflammatory Therapies (Q26786973) (← links)
- Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies (Q26799747) (← links)
- Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics (Q26822421) (← links)
- Beyond the NLRP3 inflammasome: autoinflammatory diseases reach adolescence (Q27011650) (← links)
- Early detection of sensorineural hearing loss in Muckle-Wells-syndrome (Q27303524) (← links)
- Anti-Interleukin-1 Agents in Adult Onset Still's Disease (Q27495968) (← links)
- Design of a superior cytokine antagonist for topical ophthalmic use (Q27676526) (← links)
- A preliminary score for the assessment of disease activity in hereditary recurrent fevers: results from the AIDAI (Auto-Inflammatory Diseases Activity Index) Consensus Conference. (Q27687429) (← links)
- Chronic Infantile Neurological Cutaneous and Articular (CINCA) syndrome: a review (Q28066948) (← links)
- Evasion of inflammasome activation by microbial pathogens (Q28082757) (← links)
- The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response (Q28242527) (← links)
- NLRP3 inflammasome activation induced by engineered nanomaterials (Q28387817) (← links)
- An additional piece in the puzzle of neutrophil-derived IL-1β: the NLRP3 inflammasome (Q33353321) (← links)
- Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1beta (Q33673719) (← links)
- Potential of IL-1, IL-18 and Inflammasome Inhibition for the Treatment of Inflammatory Skin Diseases. (Q33710807) (← links)
- Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens (Q33767097) (← links)
- Monogenic IL-1 mediated autoinflammatory and immunodeficiency syndromes: finding the right balance in response to danger signals (Q33798590) (← links)
- Nlrp3: an immune sensor of cellular stress and infection (Q33823177) (← links)
- Why not treat human cancer with interleukin-1 blockade? (Q33833871) (← links)
- A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome (Q33871994) (← links)
- Transcript abundance patterns in Kawasaki disease patients with intravenous immunoglobulin resistance (Q34088555) (← links)
- Averting inflammation by targeting the cytokine environment (Q34135558) (← links)
- Targeting cytokines in inflammatory diseases: focus on interleukin-1-mediated autoinflammation (Q34167205) (← links)
- Deregulated inflammasome signaling in disease (Q34212591) (← links)
- Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation (Q34254942) (← links)
- IL-1 blockade in autoinflammatory syndromes (Q34262561) (← links)
- Caspase functions in cell death and disease (Q34336335) (← links)
- Autoinflammation: the prominent role of IL-1 in monogenic autoinflammatory diseases and implications for common illnesses (Q34369278) (← links)
- A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease (Q34423486) (← links)
- Co-opting biology to deliver drugs (Q34424045) (← links)
- Monogenic autoinflammatory diseases: new insights into clinical aspects and pathogenesis (Q34489840) (← links)
- Validation of the auto-inflammatory diseases activity index (AIDAI) for hereditary recurrent fever syndromes (Q34607687) (← links)
- Advances in the understanding of familial Mediterranean fever and possibilities for targeted therapy (Q34608120) (← links)
- Rilonacept pharmacokinetics in children with systemic juvenile idiopathic arthritis (Q34771827) (← links)
- Blocking interleukin-1 in rheumatic diseases (Q34822708) (← links)
- Interleukin-1 and acute brain injury (Q35056860) (← links)
- Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey (Q35122583) (← links)
- Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives (Q35133812) (← links)
- Immunological loss-of-function due to genetic gain-of-function in humans: autosomal dominance of the third kind (Q35190461) (← links)
- Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS). (Q35557377) (← links)
- Autoinflammation: translating mechanism to therapy (Q35558406) (← links)
- Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS) (Q35620372) (← links)
- Therapy of autoinflammatory syndromes (Q35868028) (← links)